A Phase 1, Placebo-controlled, Randomized Trial To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Iv Doses Of Pf-05231023 In Obese Hyperlipidemic Adult Subjects With And Without Type 2 Diabetes Mellitus On A Background Of Atorvastatin

Phosphate Level at Baseline

时间窗: Baseline

Number of Participants With Clinically Significant Vital Sign Abnormalities

时间窗: Baseline up to Day 49

Criteria for clinically significant vital signs abnormalities included supine/sitting pulse rate of \<40 beats per minute (bpm) or \>120 bpm, supine systolic blood pressure (SBP) of \<90 millimeter of mercury (mmHg), \>=30 mmHg maximum increase and decrease from baseline in same posture, supine diastolic blood pressure (DBP) of \<50 mmHg; \>=20 mmHg maximum increase and decrease from baseline in same posture.

Number of Participants With Clinically Significant Electrocardiogram Findings

时间窗: Baseline up to Day 49

Clinically significant ECG findings included PR interval \>=300 milliseconds (msec) or \>=25 percent (%) increase from baseline (if baseline PR interval \>200 msec) or \>=50% increase (if baseline PR interval less than or equal to \[\<=\] 200 msec); QRS interval \>=140 msec or \>=50% increase from baseline; QT interval \>=500 msec, corrected QT interval based on Fridericia's formula (QTcF) 450 to \<480 msec, 480 to \<500 msec, \>=500 msec or \>=30 msec but \<60 msec increase from baseline or \>=60 msec increase from baseline.

Change From Baseline in Phosphate Level at Day 25

时间窗: Baseline, Day 25

Percent Change From Baseline in Serum N-terminal Propeptides of Type 1 Collagen (PINP) and C-Telopeptide Cross-Linking of Type 1 Collagen (CTX) Levels at Day 25

时间窗: Baseline, Day 25

Percent Change From Baseline in Blood Osteocalcin and Bone-Specific Alkaline Phosphatase Levels at Day 25

时间窗: Baseline, Day 25

Average Urinary Calcium and Phosphate Levels Over 24 Hours at Baseline

时间窗: Baseline

Change From Baseline in Average Urinary Calcium and Phosphate Levels Over 24 Hours at Day 24

时间窗: Day 24

Blood Osteocalcin and Bone-Specific Alkaline Phosphatase Levels at Baseline

时间窗: Baseline

Number of Participants With Abnormal Physical Examinations

时间窗: Baseline up to Day 49

Physical examination included general examination and examination of head, ears, eyes, nose, mouth, throat, neck, abdomen, skin, heart, lungs, lymph nodes, and gastrointestinal and musculoskeletal and neurological system.

Thyroid Stimulating Hormone (TSH) Level at Baseline

时间窗: Baseline

Results are reported in micro international units per milliliter (mcIU/mL).

Thyroid Stimulating Hormone (TSH) Level at Day 1

时间窗: Day 1

Thyroid Stimulating Hormone (TSH) Level at Day 39

时间窗: Day 39

Change From Baseline in Phosphate Level at Day 15

时间窗: Baseline, Day 15

Tartrate-resistant Acid Phosphatase Isoform 5b (TRAP 5b) Levels at Baseline

时间窗: Baseline

Percent Change From Baseline in Tartrate-resistant Acid Phosphatase Isoform 5b (TRAP 5b) Levels at Day 49

时间窗: Day 49

Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

时间窗: Baseline up to 28 days after last dose

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent events were between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pre-treatment state.

Number of Participants With Laboratory Abnormalities

时间窗: Baseline up to Day 49

Criteria for laboratory test abnormality: Hematology (hemoglobin, hematocrit, red blood corpuscles \[RBC\] count: less than \[\<\]0.8\*lower limit of normal \[LLN\], platelets: \<0.5\*LLN/greater than \[\>\]1.75\*upper limit of normal \[ULN\], leukocytes: \<0.6\*LLN or \>1.5\*ULN, lymphocytes, total neutrophils: \<0.8\*LLN or \>1.2\*ULN, basophils, eosinophil: \<0.8\*LLN, monocytes: \>1.2\*ULN); Liver Function (aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase: \>0.3\*ULN, total protein, albumin: \<0.8\*LLN or \>1.2\*ULN); total bilirubin, direct bilirubin, indirect bilirubin: \>1.5\*ULN; Renal Function (blood urea nitrogen, creatinine: \>1.3\*ULN, uric acid: \>1.2\*ULN); Electrolytes (sodium: \<0.95\*LLN or \>1.05\*ULN, potassium, chloride, calcium, bicarbonate: \<0.9\*LLN or \>1.1\*ULN; creatine kinase: \>2.0\*ULN; glucose fasting: \<0.6\*LLN or \>1.5\*ULN, urine white blood corpuscles \[WBC\] and RBC: greater than or equal to (\>=) 20/High Power Field \[HPF\]).

Thyroid Stimulating Hormone (TSH) Level at Day 25

时间窗: Day 25

Thyroid Stimulating Hormone (TSH) Level at Day 49

时间窗: Day 49

Creatine Phosphokinase (CPK) Level at Baseline

时间窗: Baseline

Change From Baseline in Creatine Phosphokinase (CPK) Level at Day 15

时间窗: Baseline, Day 15

Change From Baseline in Creatine Phosphokinase (CPK) Level at Day 49

时间窗: Baseline, Day 49

Serum N-terminal Propeptides of Type 1 Collagen (PINP) and C-Telopeptide Cross-Linking of Type 1 Collagen (CTX) Levels at Baseline

时间窗: Baseline

Percent Change From Baseline in Serum N-terminal Propeptides of Type 1 Collagen (PINP) and C-Telopeptide Cross-Linking of Type 1 Collagen (CTX) Levels at Day 39

时间窗: Baseline, Day 39

Change From Baseline in Phosphate Level at Day 8

时间窗: Baseline, Day 8

Change From Baseline in Creatine Phosphokinase (CPK) Level at Day 8

时间窗: Baseline, Day 8

Percent Change From Baseline Serum N-terminal Propeptides of Type 1 Collagen (PINP) and C-Telopeptide Cross-Linking of Type 1 Collagen (CTX) Levels at Day 49

时间窗: Baseline, Day 49

Percent Change From Baseline in Blood Osteocalcin and Bone-Specific Alkaline Phosphatase Levels at Day 39

时间窗: Baseline, Day 39

Percent Change From Baseline in Blood Osteocalcin and Bone-Specific Alkaline Phosphatase Levels at Day 49

时间窗: Baseline, Day 49

Percent Change From Baseline in Tartrate-resistant Acid Phosphatase Isoform 5b (TRAP 5b) Levels at Day 25

时间窗: Baseline, Day 25

Number of Participants With Anti-PF-05231023 Antibodies and Neutralizing Antibodies at Day 39

时间窗: Day 39

Anti-PF-05231023 antibodies and neutralizing antibodies were analyzed only for participants who received PF-05231023 as per planned analysis. One sample at Day 39 was inadvertently tested for neutralizing antibody even though the corresponding anti-PF-05231023 antibody was negative.

Number of Participants With Anti-PF-05231023 Antibodies and Neutralizing Antibodies at Day 49

时间窗: Day 49

Change From Baseline in Phosphate Level at Day 49

时间窗: Baseline, Day 49

Change From Baseline in Creatine Phosphokinase (CPK) Level at Day 25

时间窗: Baseline, Day 25

Percent Change From Baseline in Tartrate-resistant Acid Phosphatase Isoform 5b (TRAP 5b) Levels at Day 39

时间窗: Baseline, Day 39

Number of Participants With Anti-PF-05231023 Antibodies and Neutralizing Antibodies at Day 1

时间窗: Day 1

Anti-PF-05231023 antibodies and neutralizing antibodies were analyzed only for participants who received PF-05231023 as per planned analysis. One sample at Day 1 was inadvertently tested for neutralizing antibody even though the corresponding anti-PF-05231023 antibody was negative.